EBM Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dominici, F. P.
Right arrow Articles by Turyn, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dominici, F. P.
Right arrow Articles by Turyn, D.
Experimental Biology and Medicine 227:149-157 (2002)
© 2002 Society for Experimental Biology and Medicine


MINIREVIEW

Growth Hormone-Induced Alterations in the Insulin-Signaling System

Fernando P. Dominici and Daniel Turyn,1

Instituto de Química y Fisicoquímica Biológicas (UBA-CONICET), Facultad de Farmacia y Bioquímica, Junin 956 (1113), Buenos Aires, Argentina

Growth hormone (GH) counteracts insulin action on lipid and glucose metabolism. However, the sequence of molecular events leading to these changes is poorly understood. Insulin action is initiated by binding of the hormone to its cell surface receptor (IR). This event activates the intrinsic tyrosine kinase activity residing in the ß-subunit of the IR and leads to autophosphorylation of the cytoplasmic portion of the ß-subunit and further activation of its tyrosine kinase towards several intermediate proteins, including the family of IR substrates (IRS) and the Shc proteins. When tyrosine phosphorylated, these cellular substrates connect the IR with several downstream signaling molecules. One of them is the enzyme phosphatidylinositol (PI) 3-kinase. The insulin antagonistic action of GH is not a consequence of a direct interaction with the IR. Instead, long-term exposure to GH is, in general, associated with hyperinsulinemia, which leads to a reduction of IR levels and an impairment of its tyrosine kinase activity. The signals of GH and insulin may converge at post-receptor levels. The signaling pathway leading to activation of PI 3-kinase appears to be an important site of convergence between the signals of these two hormones and seems to be mediated principally by IRS-1. Rodent models of chronic GH excess have been useful tools to investigate the mechanism by which GH induces insulin resistance. Decreased IR, IRS-1, and IRS-2 tyrosyl phosphorylation in response to insulin was found in skeletal muscle, whereas a chronic activation of the IRS-PI 3-kinase pathway was found in liver. The induction of the expression of proteins that inhibit IR signaling such as suppressors of cytokine signaling (SOCS)-1 and -6 may also be involved in this alteration. Interestingly, the modulation of insulin signaling and action observed in states of GH excess, deficiency, or resistance seems to be relevant to the changes in longevity associated with those states.

Key Words: aging • diabetes • growth hormone • insulin receptor substrate • insulin signaling




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
F. A. Wilson, R. A. Orellana, A. Suryawan, H. V. Nguyen, A. S. Jeyapalan, J. Frank, and T. A. Davis
Stimulation of muscle protein synthesis by somatotropin in pigs is independent of the somatotropin-induced increase in circulating insulin
Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E187 - E194.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. U. Freda, W. Shen, S. B. Heymsfield, C. M. Reyes-Vidal, E. B. Geer, J. N. Bruce, and D. Gallagher
Lower Visceral and Subcutaneous but Higher Intermuscular Adipose Tissue Depots in Patients with Growth Hormone and Insulin-Like Growth Factor I Excess Due to Acromegaly
J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2334 - 2343.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Loffler, M. Bilban, M. Reimers, W. Waldhausl, and T. M. Stulnig
Blood Glucose-Lowering Nuclear Receptor Agonists Only Partially Normalize Hepatic Gene Expression in db/db Mice
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 797 - 804.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
J. G. Miquet, A. I. Sotelo, A. Bartke, and D. Turyn
Desensitization of the JAK2/STAT5 GH signaling pathway associated with increased CIS protein content in liver of pregnant mice
Am J Physiol Endocrinol Metab, October 1, 2005; 289(4): E600 - E607.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
K.-H. Lee, B.-H. Ko, J.-Y. Paik, K.-H. Jung, Y. S. Choe, Y. Choi, and B.-T. Kim
Effects of Anesthetic Agents and Fasting Duration on 18F-FDG Biodistribution and Insulin Levels in Tumor-Bearing Mice
J. Nucl. Med., September 1, 2005; 46(9): 1531 - 1536.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
Y. Guo, Y. Lu, D. Houle, K. Robertson, Z. Tang, J. J. Kopchick, Y. L. Liu, and J.-L. Liu
Pancreatic Islet-Specific Expression of an Insulin-Like Growth Factor-I Transgene Compensates Islet Cell Growth in Growth Hormone Receptor Gene-Deficient Mice
Endocrinology, June 1, 2005; 146(6): 2602 - 2609.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. J. Puder, S. Nilavar, K. D. Post, and P. U. Freda
Relationship between Disease-Related Morbidity and Biochemical Markers of Activity in Patients with Acromegaly
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 1972 - 1978.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
J. Rieusset, J. Seydoux, S. I. Anghel, P. Escher, L. Michalik, N. Soon Tan, D. Metzger, P. Chambon, W. Wahli, and B. Desvergne
Altered Growth in Male Peroxisome Proliferator-Activated Receptor {gamma} (PPAR{gamma}) Heterozygous Mice: Involvement of PPAR{gamma} in a Negative Feedback Regulation of Growth Hormone Action
Mol. Endocrinol., October 1, 2004; 18(10): 2363 - 2377.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
J.-L. Liu, K. T. Coschigano, K. Robertson, M. Lipsett, Y. Guo, J. J. Kopchick, U. Kumar, and Y. L. Liu
Disruption of growth hormone receptor gene causes diminished pancreatic islet size and increased insulin sensitivity in mice
Am J Physiol Endocrinol Metab, September 1, 2004; 287(3): E405 - E413.
[Abstract] [Full Text] [PDF]


Home page
J ANIM SCIHome page
J. Novakofski
Adipogenesis: Usefulness of in vitro and in vivo experimental models
J Anim Sci, March 1, 2004; 82(3): 905 - 915.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
L. A. Barbour, J. Shao, L. Qiao, W. Leitner, M. Anderson, J. E. Friedman, and B. Draznin
Human Placental Growth Hormone Increases Expression of the P85 Regulatory Unit of Phosphatidylinositol 3-Kinase and Triggers Severe Insulin Resistance in Skeletal Muscle
Endocrinology, March 1, 2004; 145(3): 1144 - 1150.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
J.A. Lemon, D.R. Boreham, and C.D. Rollo
A Dietary Supplement Abolishes Age-Related Cognitive Decline in Transgenic Mice Expressing Elevated Free Radical Processes
Experimental Biology and Medicine, July 1, 2003; 228(7): 800 - 810.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the Society for Experimental Biology and Medicine.